Format

Send to

Choose Destination
Cancer Immunol Res. 2014 Oct;2(10):926-36. doi: 10.1158/2326-6066.CIR-14-0153.

The path to reactivation of antitumor immunity and checkpoint immunotherapy.

Author information

1
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, Massachusetts. Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts.
2
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, Massachusetts. Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts. Harvey_Cantor@dfci.harvard.edu.

Abstract

Cancer immunology has recently made major therapeutic inroads that represent clinical application of basic insights into mechanisms that govern immunity against tumors. Research into fundamental elements of T-cell and natural killer-cell biology, including the basis of antigen recognition, activation, proliferation, and survival, has informed the design of new therapeutic approaches to augment the body's natural anticancer immune response. Here, we describe some of the key steps that have provided the foundation for current strategies of immunotherapy.

PMID:
25281320
DOI:
10.1158/2326-6066.CIR-14-0153
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center